No internet connection — showing the saved version of the page.

Vertex Pharmaceut…

USUSD
← to the screener

Vertex Pharmaceuticals Inc (US:VRTX) — Biotechnology: Pharmaceutical Preparations. Number of exchanges where the company shares trade: 3. On this page — price and chart, dividends, top holders and share count history.

About the company

Website
vrtx.com
Sector
Health Care · Biotechnology: Pharmaceutical Preparations
Headquarters
Boston, United States
CEO
Reshma Kewalramani
Employees
6 400
Founded
1989
Shares outstanding
253.46 M as of 2026-07-31
Free float
252.69 M
Market cap
128.36 B USD
Insiders
0.21%
Institutions
97.94%
Industry (SIC)
Pharmaceutical Preparations
ISIN
US92532F1003
LEI
54930015RAQRRZ5ZGJ91
Description

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Exchanges and tickers

ExchangeTickerCurrencyPriceType
US USA StocksVRTXUSD503.5 -0.24%common stock
LSE London Stock Exchange0QZUUSD525.23 +0.00%common stock
MX Mexican Stock ExchangeVRTXMXN—common stock

Price for 3 months

up day down day dividend ex-date payment dateHover / tap a day — open, close, high and low prices

Dividends

No dividend payments found (checked 06.10.2026). The company probably does not pay dividends.

advertisement

Top holders

HolderStakeSharesReport date
Capital World Investors10.29%26.12 M2026-06-30
Blackrock Inc.9.5%24.11 M2026-06-30
Capital Research Global…7.68%19.49 M2026-06-30
Vanguard Capital Managem…6.53%16.58 M2026-06-30
Growth Fund of America4.94%12.54 M2026-06-30
State Street Corporation4.68%11.87 M2026-06-30
VANGUARD INDEX FUNDS-Van…3.17%8.06 M2026-06-30
Invesco Ltd.3.17%8.04 M2026-06-30
VANGUARD INDEX FUNDS-Van…2.59%6.58 M2026-06-30
JPMORGAN CHASE & CO2.57%6.52 M2026-06-30
Investment Co of America2.47%6.27 M2026-06-30
Geode Capital Management…2.37%6.02 M2026-06-30
AMERICAN BALANCED FUND2.19%5.56 M2026-06-30
Invesco QQQ Trust, Serie…2.15%5.46 M2026-08-31
Vanguard Portfolio Manag…1.92%4.88 M2026-06-30
Capital International In…1.85%4.7 M2026-06-30
Amcap Fund1.83%4.65 M2026-06-30
iShares Trust-iShares Co…1.33%3.38 M2026-08-31
NEW PERSPECTIVE FUND1.33%3.37 M2026-06-30
Fidelity Concord Street…1.29%3.28 M2026-07-31
ARBUCKLE STUART A (Chief…≈0.04%100 7512025-05-13
KEWALRAMANI RESHMA (Chie…≈0.04%98 2782026-02-27
SACHDEV AMIT (Officer)≈0.03%74 0312026-07-21
TATSIS OURANIA (Officer)≈0.02%53 5722026-07-21
WAGNER CHARLES F JR (Chi…≈0.02%48 7862026-02-17
SACHS BRUCE I (Director)≈0.02%45 0002025-08-06
LEIDEN JEFFREY M (Office…≈0.02%38 7842026-02-17
ALTSHULER DAVID (Officer…≈0.01%34 4772026-01-22
LIU JOY (Officer)≈0.01%19 1312026-07-01
ATKINSON EDWARD MORROW I…≈0.01%18 4322026-02-25

Regulator events

DateRegulatorEventDetails
2026-10-02ESMAоновлення даних інструментаISIN, майданчик HAND